KFC
VRTX icon

Klingenstein Fields & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Klingenstein Fields & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$514K Buy
1,035
+30
+3% +$13.3K 0.02% 132
2026
Q1 		$449K Hold
1,005
– – 0.02% 132
2025
Q4 		$456K Hold
1,005
– – 0.02% 127
2025
Q3 		$394K Hold
1,005
– – 0.01% 134
2025
Q2 		$447K Hold
1,005
– – 0.02% 124
2025
Q1 		$487K Buy
1,005
+5
+0.5% +$2.33K 0.02% 119
2024
Q4 		$403K Hold
1,000
– – 0.02% 126
2024
Q3 		$465K Hold
1,000
– – 0.02% 124
2024
Q2 		$469K Hold
1,000
– – 0.02% 120
2024
Q1 		$418K Buy
+1,000
New +$423K 0.02% 129

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Klingenstein Fields & Co's VRTX Position: Q2 2026 in Review

Klingenstein Fields & Co increased its Vertex Pharmaceuticals (VRTX) stake by 3% in Q2 2026, buying an estimated $13.3K and bringing the position to 1,035 shares worth $514K. The position accounts for 0.02% of the portfolio, ranked #132.

Klingenstein Fields & Co first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Klingenstein Fields & Co held 1,035 shares of Vertex Pharmaceuticals worth $514K as of Q2 2026.
  • Klingenstein Fields & Co bought 30 Vertex Pharmaceuticals shares in Q2 2026, an estimated $13.3K.
  • Vertex Pharmaceuticals made up 0.02% of Klingenstein Fields & Co's portfolio in Q2 2026, its #132 holding.
  • Klingenstein Fields & Co first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Klingenstein Fields & Co's 13F filing for Q2 2026, filed 5 Aug 2026.